Noortje van Herwaarden

Dr. Noortje van Herwaarden

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 April 2015 in BMJ
Verified
Journal Article
Open access
PDF file
NHNoortje van Herwaarden
Noortje van Herwaarden
AMAatke van der Maas
Aatke van der Maas
MMMichiel J M Minten
Michiel J M Minten
FHFrank H J van Den Hoogen
Frank H J van Den Hoogen
WKWietske Kievit
Wietske Kievit
ABAlfons A Den Broeder
Alfons A Den Broeder
Objective To evaluate whether a disease activity guided strategy of dose reduction of two tumour necrosis factor (TNF) inhibitors, adalimumab or etanercept, is non-inferior in maintaining disease control in patients with rheumatoid arthritis compared with usual care. Design Randomised controlled, open label, non-inferiority strategy trial. Setting Two rheumatology outpatient clinics in the Netherlands, from December 2011 to May 2014. Participants 180 patients with rheumatoid arthritis and low disease activity using adalimumab or etanercept; 121 allocated to the dose reduction strategy, 59 to usual care. Interventions Disease activity guided dose reduction (advice to stepwise increase the injection interval every three months, until flare of disease activity or discontinuation) or usual care (no dose reduction advice). Flare was defined as increase in DAS28-CRP (a composite score measuring disease activity) greater than 1.2, or increase greater than 0.6 and current score of at least 3.2. In the case of flare, TNF inhibitor use was restarted or escalated. Main outcome measures Difference in proportions of patients with major flare (DAS28-CRP based flare longer than three months) between the two groups at 18 months, compared against a non-inferiority margin of 20%. Secondary outcomes included TNF inhibitor use at study end, functioning, quality of life, radiographic progression, and adverse events. Results Dose reduction of adalimumab or etanercept was non-inferior to usual care (proportion of patients with major flare at 18 months, 12% v 10%; difference 2%, 95% confidence interval −12% to 12%). In the dose reduction group, TNF inhibitor use could successfully be stopped in 20% (95% confidence interval 13% to 28%), the injection interval successfully increased in 43% (34% to 53%), but no dose reduction was possible in 37% (28% to 46%). Functional status, quality of life, relevant radiographic progression, and adverse events did not differ between the groups, although short lived flares (73% v 27%) and minimal radiographic progression (32% v 15%) were more frequent in dose reduction than usual care. Conclusions A disease activity guided, dose reduction strategy of adalimumab or etanercept to treat rheumatoid arthritis is non-inferior to usual care with regard to major flaring, while resulting in the successful dose reduction or stopping in two thirds of patients. Trial registration Dutch trial register (www.trialregister.nl), NTR 3216.

29 September 2014 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
NHNoortje van Herwaarden
Noortje van Herwaarden
ABAlfons A Den Broeder
Alfons A Den Broeder
WJWilco Jacobs
Wilco Jacobs
AMAatke van der Maas
Aatke van der Maas
JBJohannes Wj Bijlsma
Johannes Wj Bijlsma
BBBart(Holomeus) Jf van Den Bemt
Bart(Holomeus) Jf van Den Bemt

24 October 2013 in BMC Musculoskeletal Disorders
Verified
Journal Article
Open access
PDF file
ABAlfons A Den Broeder
Alfons A Den Broeder
NHNoortje van Herwaarden
Noortje van Herwaarden
AMAatke van der Maas
Aatke van der Maas
FHFrank Hj van Den Hoogen
Frank Hj van Den Hoogen
JBJohannes W Bijlsma
Johannes W Bijlsma
BBBart Van den Bemt
Bart Van den Bemt
Preliminary, mostly uncontrolled studies suggest that dose reduction or discontinuation of tumour necrosis factor blockers can be achieved in a relevant proportion of patients with RA without loss of disease control. However, long term safety, cost effectiveness and feasibility in clinical practice remain uncertain.

13 July 2017 in Expert Opinion on Drug Metabolism & Toxicology
Verified
Journal Article
Closed access
NHNoortje van Herwaarden
Noortje van Herwaarden
BBBart J.F. Van Den Bemt
Bart J.F. Van Den Bemt
MWMaike H.M. Wientjes
Maike H.M. Wientjes
CKCornelis Kramers
Cornelis Kramers
ABAlfons A. Den Broeder
Alfons A. Den Broeder
Introduction: Biological Disease Modifying Anti-Rheumatic Drugs (bDMARDs) have improved the treatment outcomes of inflammatory rheumatic diseases including Rheumatoid Arthritis and spondyloarthropathies. Inter-individual variation exists in (maintenance of) response to bDMARDs. Therapeutic Drug Monitoring (TDM) of bDMARDs could potentially help in optimizing treatment for the individual patient. Areas covered: Evidence of clinical utility of TDM in bDMARD treatment is reviewed. Different clinical scenarios will be discussed, including: prediction of response after start of treatment, prediction of response to a next bDMARD in case of treatment failure of the first, prediction of successful dose reduction or discontinuation in case of low disease activity, prediction of response to dose-escalation in case of active disease and prediction of response to bDMARD in case of flare in disease activity. Expert opinion: The limited available evidence does often not report important outcomes for diagnostic studies, such as sensitivity and specificity. In most clinical relevant scenarios, predictive value of serum (anti-) drug levels is absent, therefore the use of TDM of bDMARDs cannot be advocated. Well-designed prospective studies should be done to further investigate the promising scenarios to determine the place of TDM in clinical practice.

13 November 2021 in Rheumatology
Verified
Journal Article
Closed access
CBChantal A M Bouman
Chantal A M Bouman
NHNoortje van Herwaarden
Noortje van Herwaarden
ABAnnelies B Blanken
Annelies B Blanken
CLConny J Van der Laken
Conny J Van der Laken
MGMartin Gotthardt
Martin Gotthardt
CECornelia Van den Ende
Cornelia Van den Ende
Objectives: To investigate the reliability and validity of fluorine-18 fluorodeoxyglucose (18F-FDG) PET-CT scanning (FDG-PET) in RA patients with low disease activity tapering TNF inhibitors (TNFis) and its predictive value for successful tapering or discontinuation.Methods: Patients in the tapering arm of the Dose REduction Strategies of Subcutaneous TNFi study, a randomized controlled trial of TNFi tapering in RA, underwent FDG-PET before tapering (baseline) and after maximal tapering. A total of 48 joints per scan were scored both visually [FDG-avid joint (FAJ), yes/no] and quantitatively [maximal and mean standardized uptake values (SUVmax and SUVmean)]. Interobserver agreement was calculated in 10 patients at baseline. Quantitative and visual FDG-PET scores were investigated for (multilevel) association with clinical parameters both on a joint and patient level and for the predictive value at baseline and the change between baseline and maximal tapering (Δ) for successful tapering and discontinuation at 18 months.Results: A total of 79 patients underwent FDG-PET. For performance of identification of FAJs on PET, Cohen’s κ was 0.49 (range 0.35–0.63). For SUVmax and SUVmean, intraclass correlation coefficients were 0.80 (range 0.77–0.83) and 0.96 (0.9–1.0), respectively. On a joint level, swelling was significantly associated with SUVmax and SUVmean [B coefficients 1.0 (95% CI 0.73, 1.35) and 0.2 (0.08, 0.32), respectively]. On a patient level, only correlation with acute phase reactants was found. FDG-PET scores were not predictive of successful tapering or discontinuation.Conclusions: Quantitative FDG-PET arthritis scoring in RA patients with low disease activity is reliable and has some construct validity. However, no predictive values were found for FDG-PET parameters for successful tapering and/or discontinuation of TNFi.

1 April 2025 in RMD Open
Verified
Journal Article
Open access
PDF file
IEIlse van Es
Ilse van Es
JVJohanna E Vriezekolk
Johanna E Vriezekolk
NBNathan Den Broeder
Nathan Den Broeder
LBLisan de Beijer
Lisan de Beijer
ABAlfons A Den Broeder
Alfons A Den Broeder
ELEmmerik F A Leijten
Emmerik F A Leijten
Objectives: To compare a bDMARD mode of action cycle vs swap treatment strategy in patients with psoriatic arthritis (PsA) or axial spondyloarthritis (axSpA) after first tumour necrosis factor inhibitor (TNFi) discontinuation. Methods: In December 2019, our local treatment protocol for PsA and axSpA changed from a cycle strategy (first TNFi to second TNFi) to a swap strategy (first TNFi to IL-17i). We performed a retrospective comparison of the 3-year drug retention rate using multivariable Cox regression (ref: cycle group) and disease activity (DAS28-CRP for PsA, BASDAI for axSpA) in patients with a clinical diagnosis of PsA and axSpA. For subgroup analyses, Cox regression models were stratified by sex, reason of first TNFi discontinuation, and (non-)radiographic status in axSpA. Results: In PsA patients (n=406), there was no overall significant difference in drug retention between strategies (HR: 1.17 (95% CI: 0.87 to 1.58), p=0.29), but male PsA patients had a significant higher risk for treatment discontinuation following a swap strategy. In axSpA patients (n=335), the swap strategy was overall associated with a higher risk of treatment discontinuation (HR: 1.46 (95% CI: 1.03 to 2.07), p=0.04). Patients who discontinued their first TNFi due to inefficacy and patients diagnosed with radiographic axSpA were at significant higher risk for treatment discontinuation following a swap strategy. No significant differences in disease activity were found for treatment strategies in PsA or axSpA. Conclusion: In PsA, the cycle and swap treatment strategy performed similarly, while in axSpA, the cycle strategy was associated with a significant higher drug retention rate.